Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
AML
Interventions
BIOLOGICAL

APVO436

"APVO436~Dosage: APVO436 will be administered at a fixed dosage of 18 mcg after a weekly ramp up during Cycle 1 (Step-up dosing: C1D15: 6 mcg over 22 hours, C1D22: 12 mcg over 8 hours, C2D1: 18 mcg over 6 hours, C2D8: 18 mcg over 4 hours), totaling 18 µg in Cycle 1 and 72 µg/cycle for Cycles 2-4 for a total of 234 µg for the projected 4-cycle treatment course.~Dosage Form: IV Solutions for Intravenous Administration~Frequency: Weekly"

Sponsors
All Listed Sponsors
lead

Aptevo Therapeutics

INDUSTRY